Ann: Appendix 4D and Half Year Report, page-15

The intellectual property license between Cellmid and Lyramid has been amended from
a royalty free arrangement to 4% royalty on sales of products developed as a result of
the licensed midkine intellectual property and 8% royalty on sublicense revenue. The term
of the license is five years after all patent rights expire, whether current patents or patents
arising out of existing midkine intellectual property.

What does that mean to you Dentie/ Ozjin